Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
- PMID: 20685771
- DOI: 10.1177/1078155210378913
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
Abstract
Tyrosine kinase is a key enzyme activity utilized in many intracellular messaging pathways. Understanding the role of particular tyrosine kinases in malignancies has allowed for the design of tyrosine kinase inhibitors (TKIs), which can target these enzymes and interfere with downstream signaling. TKIs have proven to be successful in the treatment of chronic myeloid leukemia, renal cell carcinoma and gastrointestinal stromal tumor, and other malignancies. Scattered reports have suggested that these agents appear to affect blood glucose (BG). We retrospectively studied the BG concentrations in diabetic (17) and nondiabetic (61) patients treated with dasatinib (8), imatinib (39), sorafenib (23), and sunitinib (30) in our clinical practice. Mean declines of BG were dasatinib (53 mg/dL), imatinib (9 mg/dL), sorafenib (12 mg/dL), and sunitinib (14 mg/dL). All these declines in BG were statistically significant. Of note, 47% (8/17) of the patients with diabetes were able to discontinue their medications, including insulin in some patients. Only one diabetic patient developed symptomatic hypoglycemia while on sunitinib. The mechanism for the hypoglycemic effect of these drugs is unclear, but of the four agents tested, c-kit and PDGFRβ are the common target kinases. Clinicians should keep the potential hypoglycemic effects of these agents in mind; modification of hypoglycemic agents may be required in diabetic patients. These results also suggest that inhibition of a tyrosine kinase, be it c-kit, PDGFRβ or some other undefined target, may improve diabetes mellitus BG control and it deserves further study as a potential novel therapeutic option.
Similar articles
-
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].Endocrinol Nutr. 2011 Feb;58(2):94-6. doi: 10.1016/j.endonu.2010.09.012. Epub 2011 Feb 17. Endocrinol Nutr. 2011. PMID: 21333617 Spanish. No abstract available.
-
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96. doi: 10.1016/j.jchromb.2009.04.045. Epub 2009 May 13. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19505856
-
Current and future management of GIST.Clin Adv Hematol Oncol. 2006 Aug;4(8):582-3. Clin Adv Hematol Oncol. 2006. PMID: 17099615 No abstract available.
-
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].Bull Cancer. 2007 Oct;94(10):871-80. Bull Cancer. 2007. PMID: 17964981 Review. French.
-
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].Bull Cancer. 2008 Jan;95(1):107-16. doi: 10.1684/bdc.2008.0561. Bull Cancer. 2008. PMID: 18230576 Review. French.
Cited by
-
A PKM2 signature in the failing heart.Biochem Biophys Res Commun. 2015 Apr 10;459(3):430-6. doi: 10.1016/j.bbrc.2015.02.122. Epub 2015 Feb 28. Biochem Biophys Res Commun. 2015. PMID: 25735978 Free PMC article.
-
Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update.Int J Mol Sci. 2022 Oct 16;23(20):12376. doi: 10.3390/ijms232012376. Int J Mol Sci. 2022. PMID: 36293233 Free PMC article. Review.
-
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.Front Physiol. 2021 Jul 5;12:675811. doi: 10.3389/fphys.2021.675811. eCollection 2021. Front Physiol. 2021. PMID: 34290617 Free PMC article. Review.
-
Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors.J Clin Med. 2024 May 31;13(11):3269. doi: 10.3390/jcm13113269. J Clin Med. 2024. PMID: 38892979 Free PMC article.
-
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.BMC Endocr Disord. 2018 Nov 3;18(1):77. doi: 10.1186/s12902-018-0303-x. BMC Endocr Disord. 2018. PMID: 30390651 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical